Compare GSK plc (GSK) vs National Energy Services Reunited Corp Ordinary Shares (NESR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs National Energy Services Reunited Corp Ordinary Shares — how do they compare? GSK plc trades at $47.87 (market cap $92.78B), while National Energy Services Reunited Corp Ordinary Shares trades at $19.71 (market cap $2.12B). The key difference: GSK plc is far larger — about 43.8× National Energy Services Reunited Corp Ordinary Shares's market cap, and GSK plc pays a 3.92% dividend while National Energy Services Reunited Corp Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and National Energy Services Reunited Corp Ordinary Shares for 0 Days on average.
| GSK | NESR | |
|---|---|---|
Market Cap | $92.78B | $2.12B |
Volume | 5,756,402 | 3,257,316 |
Sector | Health | Energy |
52-Week High | $61.18 | $36.31 |
52-Week Low | $43.24 | $10.41 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $112.77B | $2.24B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About National Energy Services Reunited Corp Ordinary Shares
National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →
